Drafting confidentiality agreements in the context of mergers and acquisitions (M&A) is a critical step that sets the stage for a smooth and secure transaction. These agreements, also referred to as non-disclosure agreements (NDAs), help protect sensitive information shared during the negotiation process and establish clear expectations for both parties. A well-crafted confidentiality agreement builds trust, mitigates risks, and preserves the commercial and competitive value of disclosed materials. However, poorly constructed agreements can lead to disputes, loss of confidential information, or exposure to legal liabilities. This article examines the key considerations to bear in mind when drafting M&A confidentiality agreements.
Understanding the Purpose of Confidentiality Agreements
Confidentiality agreements in M&A transactions are designed to safeguard proprietary or commercially sensitive information that might be exchanged during negotiations or due diligence. The party seeking to sell or merge its business typically allows potential buyers or investors access to internal documents, financial data, intellectual property details, and customer or supplier records. Protecting this information from misuse, disclosure, or being leveraged by competitors is paramount. Simultaneously, these agreements preserve trust between the parties and provide a framework for addressing potential breaches.
Given the high-stakes nature of M&A deals—often involving significant financial sums and long-term strategic goals—it is essential that the confidentiality agreement is not approached as a generic or boilerplate document. Instead, careful thought must go into its terms, ensuring it addresses the unique intricacies of the transaction and the industry in which the parties operate.
Defining Confidential Information Clearly
One of the cornerstones of any confidentiality agreement is defining what constitutes confidential information. This definition must be precise yet encompassing. Overly vague definitions can leave room for interpretation, while excessively broad descriptions may deem information confidential even when it is already public knowledge or unrelated to the deal.
Typically, confidential information includes business records, trade secrets, technical know-how, marketing strategies, financial statements, business plans, product designs, software code, and supplier or customer details. However, the definition must take into account the specific context of the M&A transaction. For example, in technology deals, source codes and algorithms may require special attention, while in retail acquisitions, customer data and buying patterns could warrant heightened scrutiny.
Equally important is clearly identifying exclusions. Certain categories of information should not be classified as confidential, such as data already in the public domain, information already known to the receiving party, or disclosures required by law. Specifying these exceptions prevents confusion and potential disagreements down the line.
Mutual versus Unilateral Agreements
Another important consideration is whether the confidentiality agreement should be unilateral or mutual. In a unilateral agreement, only one party discloses sensitive information, while the receiving party assumes the obligation to maintain confidentiality. This is most common when a seller or target company provides information to a prospective buyer.
In contrast, mutual NDAs require both parties to treat shared information with confidentiality. Such agreements are typically used when both parties need to disclose sensitive information, for example, in joint venture discussions or two-sided due diligence processes. Businesses must carefully evaluate the nature of the M&A transaction to determine whether a unilateral or mutual approach is most appropriate.
The Duration of Confidentiality Obligations
The question of how long confidentiality obligations should last is often a contentious point in agreement negotiations. On one hand, the disclosing party wishes to ensure its information is protected indefinitely. On the other, the receiving party may not want to assume open-ended liability, particularly if the information loses its commercial relevance over time.
Striking the right balance requires assessing the type of information being shared. For trade secrets and highly sensitive competitive information, a longer duration—or even indefinite confidentiality—might be appropriate. Conversely, for less critical information, a term of three to five years is often reasonable. Parties should also consider the evolving nature of the industry and technology when determining the agreement’s time frame.
Restrictions on Permitted Use of Information
M&A confidentiality agreements should explicitly spell out the purpose for which the disclosed information can be used. Limiting its use solely to evaluating the proposed transaction is standard practice, as it ensures the receiving party does not exploit the information for unrelated commercial gains or gain a competitive edge.
To avoid ambiguity, the agreement should include specific language barring the receiving party from using the information to solicit employees, customers, or suppliers of the disclosing party—a protection known as non-solicitation. Similarly, inserting a restriction on reverse engineering or analysing disclosed materials (if relevant to the transaction) is another precautionary measure to mitigate misuse.
Disclosure to Third Parties
During the course of M&A due diligence, sensitive information may need to be shared with third parties such as legal advisors, financial consultants, or accountants. The confidentiality agreement should address how this third-party disclosure will be handled. It is common to allow disclosure to third parties on a “need-to-know” basis, provided they are bound by confidentiality obligations at least as stringent as those outlined in the primary agreement.
Furthermore, disclosing parties may wish to retain the ability to approve in advance which third parties can access their information. Another safeguard is requiring the receiving party to disclose the identity of any third parties to whom information is provided.
Addressing Legal and Regulatory Disclosures
In certain situations, the receiving party may be legally compelled to disclose confidential information, such as complying with subpoena requests, court orders, or regulatory filings. It is vital for confidentiality agreements to include a carve-out for such situations, allowing disclosure when required by law. However, allowing unrestricted legal disclosures could create risks, so agreements often require the receiving party to provide advance notice to the disclosing party and cooperate in seeking protective orders or other remedies to minimise exposure.
Remedies for Breach
The inclusion of remedies for breach is another essential aspect when drafting M&A confidentiality agreements. Breaches can have far-reaching consequences, including loss of competitive advantage, reputational damage, or financial losses. Common remedies include monetary damages, injunctive relief, or specific performance (enforcing the agreement’s terms).
In practice, addressing breaches promptly is critical. Injunctive relief, which restrains the breaching party from further disseminating or using the information, can often prevent more severe harm. Detailing the use of arbitration or other dispute resolution mechanisms is also prudent, as it ensures a structured approach to resolving conflicts.
Governing Law and Jurisdiction
In cross-border transactions, where the parties may reside in different countries, specifying the governing law and jurisdiction of the confidentiality agreement is indispensable. This decision determines how the agreement will be interpreted, as well as where disputes will be resolved. Disclosing parties typically prefer the laws of their home jurisdiction or a neutral jurisdiction favourable to dispute resolution. Parties should collaborate with legal counsel to understand the implications of their choice and address any differences in legal frameworks.
Tailoring Agreements to Industry Practices
Every industry operates with its own norms, and these norms must inform how confidentiality agreements are drafted. For example, the pharmaceutical and biotechnology sectors often involve lengthy research and development cycles, necessitating extended confidentiality protections. In contrast, technology start-ups may focus more heavily on protecting intellectual property. Understanding industry-specific risks enables more effective mitigation strategies and ensures the agreement aligns with commercial realities.
Adding Non-Circumvention Clauses
A non-circumvention clause is a useful addition to confidentiality agreements in M&A deals. Such clauses prohibit the receiving party from bypassing the disclosing party to engage directly with suppliers, customers, or other stakeholders without consent. Non-circumvention provisions preserve the disclosing party’s business relationships and prevent misuse of the disclosed information.
Final Thoughts
Drafting M&A confidentiality agreements is not a one-size-fits-all exercise. These foundational documents must be tailored to the specific transaction, considering the nature of the business, the sensitivity of the information, the scope of due diligence, and potential risks. Thoughtful drafting not only protects each party’s interests but also paves the way for a trustworthy and efficient negotiation process.
Ultimately, the key to success lies in detailed communication between the parties and the involvement of experienced legal counsel. By anticipating potential issues and addressing them proactively within the agreement, parties can focus on the broader objectives of the transaction and work towards a mutually beneficial outcome.